Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer

NCT04725994 is registered in ClinicalTrials.gov with Idience Co., Ltd. as lead sponsor.

NCT NCT04725994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04725994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer
Lead sponsor
Idience Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 28, 2021
Completion date
March 31, 2027
Enrollment
87 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer